CENCORA INC 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Cencora reported a strong Q3 fiscal 2026, with revenue of $84.8B, up 5% year over year, driven by growth in both core segments and Other. Adjusted gross profit rose 23% to $3.5B, with gross margin expanding 61 bps to 4.16%, helped by the OneOncology acquisition. Adjusted operating income increased 17% to $1.2B, and adjusted EPS grew 12%, supported by $1B of share repurchases. U.S. Healthcare Solutions operating income grew 16% to $966M, while International Healthcare Solutions operating income increased 21% to $166M.

Company Outlook & Strategy: Management raised FY2026 adjusted EPS guidance to $17.75–$17.95 and increased the low end of consolidated operating income growth guidance to 13%–14%. The company reiterated confidence in its pharmaceutical-centric strategy, with emphasis on specialty care, digital transformation, and disciplined capital deployment. Management highlighted continued strength in U.S. and International Healthcare Solutions and said it will provide full FY2027 guidance on the November call.

Key Industry Trends: The company noted that the market is still digesting and annualizing manufacturer list price changes, which created a revenue headwind. Specialty care continues to grow more complex, increasing demand for distribution, access, reimbursement, and administrative support. Part B biosimilars were described as an ongoing opportunity to lower system costs and improve patient access. Internationally, results benefited from timing of manufacturer price adjustments in a developing market country.

Operational Highlights: Specialty remained a key growth driver across health systems, physician practices, MSOs, and community providers. GLP-1 sales increased $2.3B year over year, though partially offset by list price reductions and customer losses. OneOncology and RCA outperformed expectations, and AI-enabled demand forecasting was highlighted as part of the company’s digital transformation. The company also noted strong execution in European distribution, World Courier, and European 3PL, plus progress on debt reduction with the full repayment of the $800M RCA term loan.

Challenges & Risks: Revenue growth was pressured by $2.4B of manufacturer list price reductions, the loss of an oncology customer in 2025, and lower sales to a large mail-order customer. Net interest expense increased due to acquisition-related debt, though partially offset by debt paydown. Management also flagged FX pressure in International Healthcare Solutions and noted uncertainty around the timing of the MWI-Covetrus merger and the EyeSouth Retina carve-out.

Key Analyst Questions & Responses: Analysts asked about the apparent reacceleration in U.S. pharma/pharmaceutical distribution, and management attributed the outperformance mainly to strong MSO performance, specialty strength in physician and health system channels, and OneOncology exceeding expectations. On FY2027, management said Cencora remains confident in its long-term outlook but will provide formal 2027 guidance on the November call; it did not directly confirm consensus estimates but indicated the core business remains well positioned for continued growth.